This article is more than 5 years old. Information may no longer be current.

Sandoz files appeal in patent infringement lawsuit

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Sandoz has filed an appeal of a recent court judgment that upheld the patents protecting AzaSite, according to a press release from InSite Vision.

The appeal was filed in the United States Court of Appeals for the Federal Circuit.

In 2011, Sandoz filed an abbreviated new drug application with the U.S. Food and Drug Administration to market a generic version of AzaSite (azithromycin 1% ophthalmic solution, InSite) before expiration of the patents that cover AzaSite and its use, the release said.

In response, InSite brought a patent infringement lawsuit against Sandoz, and on Oct. 7, the United States District Court for the District of New Jersey ruled in favor of InSite, upholding all four of the patents.